Paul Vs The Market

I don’t know how to start this quarterly update.

Just a month ago, I was watching the Freedom Portfolio have a scorching start to the new decade thanks to the incredible run of companies like Tesla (TSLA). I was even wondering if I might be able to talk about how the portfolio had managed to double over a mere 15 months. That kind of thinking seems patently ridiculous now.

For those unaware, this past month has seen the fastest market drop in history as COVID-19 (aka, Coronavirus) has brought the US economy to a screeching halt. The volatility has been extreme, and it has gotten to the point where I don’t even blink when multiple positions in the Freedom Portfolio are up (or down) 20%+ in a day. Redfin (RDFN) was recently up 20% and 30% in back-to-back days and is still down something close to 50% in the past month alone. So I’ve very quickly had to shift my mindset from one of, “Isn’t the market an amazing way to generate wealth?” to “Don’t panic! This kind of thing happens sometimes”.

After some consideration, I decided that I wanted to get one main point across with this quarterly update: That I am completely and utterly unfazed by what the stock market has done this quarter.

I laid out most of my thoughts in my previous article: Don’t Panic (and also: COVID-19 Update: What a month), but the short version is this: I was investing during the Great Financial Crisis. I know that markets often go down and the drop is often much faster than when it goes up. Volatility like this is the price paid for superior long term returns. I don’t know where the market will go over the coming months or even year, but I am very confident that over the next 5+ years (which is my investing time frame), that the market will be up from where it is now. Throughout this entire market drop, I only sold one position and immediately re-allocated those funds to another (new) position. I stayed invested in stocks the entire time and even increased my 401(k) contribution and shifted some of my emergency fund money from CDs to the market. I am not calling a bottom, but I am absolutely convinced that stocks are on sale right now for anybody who has a 5+ year time horizon like I do.

Before I get to the results for this past quarter, I want to make a very important note. The market has been extremely volatile lately, and it hasn’t been uncommon for the market to move more in a single day than it has in some previous months or years. I saw one stat that said, “In 2017 the S&P had daily moves of more than 1% 8 times. In the last 27 trading days it’s happened 21 times.”

All this is to say that the numbers contained below are very tentative and could easily be out of date by the time you read this. I typically like to write these quarterly updates a week or two in advance, and most of these numbers will be coming from March 26th/27th, but who knows how things might change by the time April 1st comes along. If things change too much, I suppose I can always write this article off as an April Fool’s Day joke.

So basically, treat the numbers below as very tentative.

With that being said, it looks like the Freedom Portfolio will end up down around 6% for the first quarter of 2020. That’s not good, but still far better than the S&P 500, which is down roughly 21%. Since inception, the Freedom Portfolio is now convincingly beating the S&P with a positive return of 4% versus a negative return of 11% for the S&P. That’s an outperformance of 15 percentage points over a year and a half.

In terms of beating the market, that’s a pretty great quarter for the Freedom Portfolio. Obviously, it’s a bit of a mixed bag because my portfolio has lost tens of thousands of dollars over a mere 30 days, which is almost certainly the biggest loss of wealth I’ve ever experienced in my life in that short of an amount of time, but I am pleased that my portfolio has held up better than the market overall during these trying times and has opened up a convincing lead. Here’s hoping the Freedom Portfolio can expand that lead as the market rebounds.

Here is the performance broken down by position over the past quarter:

Notable Performers

Best Performers

Teladoc (TDOC): It should be no secret why Teladoc had an amazing quarter. I don’t want to make light of a situation which is killing people and obviously Teladoc management would never want to phrase it this way, but you couldn’t have written up a better script for Teladoc than a highly contagious pandemic where the government is encouraging people to practice social distancing. I had invested in Teladoc because I thought telemedicine would be big in the future and COVID-19 seems to have only accelerated that future to now.

Tesla (TSLA): Tesla shows up as a big winner, but it almost feels like a loser to me. Why? Because just around a month and a half ago, Tesla was above $900 a share and absolutely crushing it with early Model Y deliveries and promises of shoring up their balance sheet with secondary offerings and actual profit. Now, the stock is barely above $500 a share and factories are (begrudgingly) being shut down. It has still been an amazing run for the company over the past six months, though, and the future still looks bright.

JD.com (JD): It’s probably a surprise to most people, but China’s stock market has been one of the best performing (if not the best performing) market in the world in 2020. JD.com was basically born during the SARS epidemic when its founder decided to take advantage of the opportunity to sell things online and it sounds like it has been able to come through this COVID-19 crisis stronger as well.

Worst Performers

Jumia Technologies (JMIA): Another quarter, another appearance on the “worst performers” list. I’ve run out of things to say about Jumia. It has flat out been an awful investment so far. I’m probably holding on for now, especially since it has shrunk to such a small position, but I’m definitely not looking to add any more shares.

Kushco Holdings (KSHB): Everything from above can be said for Kushco as well. There’s a possibility of a rebound if/when vaping bounces back and/or marijuana becomes legalized at the federal level in the United States, but those hopes aren’t big enough to buy more shares. Like with Jumia, I am tempted to close out this position.

Roku (ROKU): I’m not sure I understand why Roku has sold off as much as it has this quarter. My best guess is that it has less to do with the company itself and more to do with the sector it is in: connected TV and advertising focused companies. Not only was Roku down big this quarter, but so were companies like The Trade Desk (TTD) and Teleria (TLRA). Perhaps the market is concerned that there will be less money spent on advertising during a recession? Regardless, I’m unconcerned about this drop so far.

Disney (DIS): While it’s a mystery to me why Roku is down big, it’s no mystery at all why Disney has been crushed in the wake of COVID-19. Their amusement parks have been shut down to help prevent the spread of the disease and movie theaters have also been shut down, meaning they can’t release movies like Mulan and Black Widow. Even their TV properties are likely struggling with ESPN having so little professional sports to cover. Maybe they’re seeing a slight bump in Disney+ adoption due to social distancing, but it’s not nearly enough to offset the damage being done elsewhere. No wonder Bob Iger jumped ship early. Disney is going to have some tough earnings reports coming up (especially compared to the incredible year they had last year), and the timing is rough since they just spent a ton of money acquiring Fox and ownership of Hulu, but I still believe in Disney over the long term. I’m holding tight.

Changes in the Portfolio

It’s worth noting that the majority of the moves below were made before the market tanked. Since February 21st, the only moves I have made are the MondoDB sell and the Livongo Health buy. All of the other changes were made earlier in the year and were mostly focused on trying to concentrate my portfolio down into fewer positions (something I alluded to wanting to do in my previous quarterly recap).

Sells

Abiomed (ABMD): I was beginning to lose hope in the promised turnaround and was beginning to wonder if the damage had already been done and would ever fully get reversed. Once the seed of doubt is planted that a medical device might be unsafe, how many studies is it going to take to remove that doubt? Does Abiomed have a second act to rely on? I had lost my conviction in the company, and decided that meant it was time to sell.

StoneCo (STNE): I had bought StoneCo because I loved the idea of buying the “Square of Latin America” and also liked seeing that Berkshire Hathaway had a position in the company. However, I kept struggling with the fact that I hardly knew anything about the company outside of earnings reports. Also, one of the main reasons I love Square is their Cash App, which is something that StoneCo doesn’t seem to have (but possible competitor and other Freedom Portfolio holding Mercado Libre (MELI) does have). This was a lower conviction holding, and I felt like the money was better invested in another company I had a higher conviction in.

MongoDB (MDB): There’s a saying that I like that says, “you can’t borrow conviction”. MongoDB was increasingly feeling like a stock where I was trying to borrow conviction from others. A lot of smart investors I know are high on MongoDB, which is why I had dipped my toe in with a small position. However, I always struggled to understand what gave it an advantage over similar offerings from Amazon (AMZN). It has eternally languished as one of my lower conviction positions and this year I finally decided to close it out to put the funds to better use in higher conviction picks.

Alibaba (BABA): One of my initial reasons for investing in Alibaba was because I liked a lot of the opportunities they seemed to have expanding their eCommerce operations outside of China (specifically Southeast Asia). With my recent purchase of Sea Limited (SE), that itch has been scratched, and there was one less reason to invest in Alibaba. I liked the Chinese exposure that I was getting from the JIB stocks, so it felt like the time to put those funds to better use somewhere else.

Buys

Livongo Health (LVGO): This is a buy from last quarter’s watchlist. I was really interested in their business model, which uses AI to provide “nudges” to people dealing with chronic diseases like diabetes and high blood pressure. It’s a subscription model that appears to be growing nicely and has some good data to back up how it helps improve health outcomes and also save money. They also have held up surprisingly well over the past month for some reason, which is a nice bonus.

Additions to already existing positions: Roku (ROKU), Teleria (TLRA), Yext (YEXT).

Watchlist

I’ve been pretty inactive in terms of buying and/or selling positions in the Freedom Portfolio during this COVID-19 induced market drop because I don’t like to make rash decisions. However, seeing a lot of my positions losing 30%, 40%, or even 50% of their value has really illuminated which companies I really believe in (and want to buy more of) and which have me worried (and make me want to sell). There’s a decent chance I purge some of those companies in the coming quarter in order to load up on some of those companies that I believe i more. In addition to possibly adding to positions I already have, here is what is on my watchlist to buy or sell in the coming quarter:

Luckin Coffee (LK) – China has a lot of people, and they’re not nearly as obsessed with coffee as Americans are… yet. I’m intrigued by this China-based, mobile app / kiosk focused coffee company. The stock is down about 50% from its recent highs, and I’m tempted to dip my toe in now. If it drops more (presumably after some pretty bad earnings reports due to China’s lockdown) then I’ll be even more tempted.

Spotify (SPOT) – Spotify used to be in the Freedom Portfolio, but I sold because I lost conviction in it. I never stopped being intrigued by the company, though, and continue to be impressed by the moves they are making to become the Netflix of audio. Purchasing The Ringer (and their stable of popular podcasts) could be huge and could give them something that differentiates them from things like Amazon Music and Apple Music. I’ll be watching with interest to see what their next moves are.

KushCo and Jumia – See above. These two companies have been awful performers over many quarters, and I’m not sure I can see daylight at the end of the tunnel anymore. I have no plans to sell right now, but the thought has crossed my mind a few times.

Crispr (CRSP) and Editas (EDIT) – It’s really hard for me to have that strong of conviction when it comes to areas I know so little about. Everybody tells me that CRISPR is going to be huge, and I believe them, but I don’t have a strong sense of how to judge which companies are best positioned to take advantage or even how to measure how progress is going. Since I am trying to concentrate my portfolio on my higher conviction picks, then, these two have to be under consideration for being on the chopping block.

Guardant Health (GH) – Similar to the above, I’m far from a healthcare expert, and so it’s hard for me to judge just how good of a moat Guardant Health has and how susceptible they are to disruption. Another company I might consider selling to raise funds to buy something else.

The Freedom Portfolio – April 2020

Due to the incredible volatility in the market the past month or so, the Freedom Portfolio has seen more change than usual. Former Babylon 5 sized position Mercado Libre has shrunk back to an Enterprise level position. Former Serenity sized positions Teladoc, Tesla, and Netflix have surged into Enterprise level positions, and there has been a lot of switching up between Serenity and Millenium Falcon sized positions as well. Will things return to normal once everything related to COVID-19 settles down? Or will Tesla and Teladoc be permanent fixtures among the Enterprise and above levels? I guess we’ll find out.

Thanks, as always, for reading. I hope you all manage to stay safe during these extraordinary times. And remember: Wash your hands.

2019 is in the books! It’s time for another quarterly Freedom Portfolio update. Sorry this update is a little late. Over the past few weeks I’ve been juggling the typical holiday hecticness, setting up the next season of Fantasy Investing (new post coming soon!), trying to stick to a New Year’s Resolution to workout more, and dealing with 3 separate cases of flu in the family.

The fourth quarter was a pretty great one for the Freedom Portfolio, which was up a strong 16% versus roughly 9% for the S&P 500. Since inception, the Freedom Portfolio is now up 11.2% versus 10.4% for the S&P 500. It’s not a huge amount of out-performance, but it’s still a relatively short time frame when it comes to my investing horizon.

Here is the performance broken down by position over the past quarter:

Notable Performers

Best Performers

Tesla (TSLA): Even for a volatile stock like Tesla, the fourth quarter was a little crazy. Positive news regarding Model 3 deliveries in the US and deliveries in China ramping up earlier than expected seemed to be enough to send shorts scurrying for the exit. Even the widely panned (at the time) Cybertruck demonstration didn’t seem to hurt the stock momentum much (possibly because of the higher than expected number of reservations that Elon Musk announced?). There are still plenty of risks with Tesla, but much like the end of the year last year, they seem to be going into the new year with the good news outweighing the bad… for now.

CRISPR Therapeutics (CRSP): The fourth quarter of 2019 saw some promising news in terms of the types of benefits people were hoping to see from CRISPR (the technology, not the company). That appears to be the biggest reason why CRISPR (the company, not the technology) and Editas (EDIT) both saw big bumps over the past few months. In the case of CRISPR, it was enough of a bump to push it from a Millenium Falcon position to a Serenity level position.

ShockWave Medical (SWAV): It’s a little unclear to me exactly what happened with ShockWave Medical over the past quarter, since there didn’t appear to be any significant news which should’ve moved the stock. My best guess is that, because the IPO lockup period ended on September 3rd, it’s possible a lot of insiders sold their shares (which depressed the price of the stock) and once the selling was over (coincidentally right around the start of the quarter), the stock rebounded some.

ShockWave is actually an interesting case study regarding the dangers of investing in recently IPO’d companies. I typically try to wait before investing in recent IPOs, but broke my rule twice in 2019 (Jumia and ShockWave) and got burned both times. It’s easy to get caught up in the euphoria surrounding an IPO and then get caught owning a stock that plummets once that euphoria wears off. The same pattern happened a lot with IPOs in 2019 where the stock went crazy in the first few months before crashing back down to Earth. Just look at Beyond Meat (BYND)!

The lesson learned for me? Don’t get caught up in the excitement around an IPO, and especially don’t get caught up in feelings of FOMO when an interesting stock keeps going up to ridiculous heights. Chances are good there will be a better entry price once the lockup period ends and the excitement wears off. I’m still bullish on ShockWave, but I do wish I had waited longer to start my position.

The Trade Desk (TTD): Another head-scratcher. While The Trade Desk was up 40%+ the past quarter, if you zoom out a little more you would see that appreciation just about brings it back to where it was in the middle of 2019. A number of high-growth, high-valuation software as a service (SaaS) companies saw some dips in the third quarter of 2019, so this rebound seems like it’s just a recovery from that previous dip.

Worst Performers

Baozun (BZUN): Baozun’s most recent earnings report was pretty good, and contained some strong growth across the board, but it also contained forward guidance which seemed to disappoint investors. I knew that Baozun was likely to be a volatile stock, and the past few years has likely been tough in terms of a slowing Chinese economy and the trade war, so I’m not overly concerned. Still, I’ll be interested to see what their next earnings report looks like. If it looks like there are signs of permanently slowing growth, then it might be time to consider selling.

Invitae (NVTA): Invitae is another stock that I expected volatility from. As of mid-2019 it had almost doubled, so I’m not surprised to see it give some of those gains back later in the year. No huge concerns for me here.

Jumia Technologies (JMIA): Jumia falls squarely into the “recent IPO that I should’ve waited longer to invest in” camp that I mentioned above. I’m still a believer in the eCommerce opportunity in Africa, but in retrospect Jumia was clearly way overvalued and is now sitting considerably below its IPO price. I should’ve waited to see how the company performed for a few quarters instead of jumping in so soon. I excepted a ton of volatility from Jumia (even more than from the companies above), so the drop in stock price doesn’t concern me, although I’ll definitely be keeping an eye on how the company continues to perform. They’re burning through a lot of cash and profitability seems very far away. This remains possibly the riskiest position in the Freedom Portfolio.

Changes in the Portfolio

There was a saying I came across recently which essentially said that every new addition to your portfolio should be better than what you already own, or else you are diluting your returns. It was something that really spoke to me. I always envisioned the ideal number of positions for the Freedom Portfolio being somewhere between 20 and 25, even though I knew that would be hard to stick to. Sure enough, the Freedom Portfolio had ballooned to over 30 positions as of the last check-in. As a result, for the past few months I’ve tried to focus on reducing the number of positions I have by eliminating those I have lower conviction in. You’ll probably see that reflected below.

Sells

Twilio (TWLO): One concern that I have had over the past few months is the performance of software as a service (SaaS) stocks possibly getting ahead of the underlying businesses. I sold my entire position in Twilio because it was one of my lower conviction SaaS companies where I felt like I didn’t fully understand their competitive advantage enough.

Intuitive Surgical (ISRG): Another lower conviction positions that I sold completely out of. I’m still really interested in the robotic assisted surgery space, but there are other opportunities I’m more excited about right now.

Illumina (ILMN): It’s a similar story with Illumina. They’ve run into some slower growth and some speed bumps with their Pacific Bio acquisition. There are enough dark clouds around the company right now that I just didn’t want to have to deal with.

Prosus (PROSY) and Naspers (NPSNY): Prosus was a spin-off of Naspers that happened earlier in the year. Both were intended to be indirect ways to invest in Tencent while getting some exposure to other companies as well. It’s hard to think of a better way to simplify my portfolio than to drop Prosus and Naspers. It helps that I have become concerned about the Chinese government’s increasing scrutiny of Tencent’s gaming business.

Buys

Roku (ROKU): Most people probably only think of the small hardware devices when they think of Roku, but they also have a growing advertising business. With the streaming video wars seemingly heating up with the release of Disney + and Apple TV +, I’ve become more interested in different ways to invest in the connected TV space and Roku seems like a good one.

Telaria (TLRA): Like Roku, Telaria is another way to invest in advertising in the connected TV future. It’s a small company, so I’m starting with a small position right now while I see how the company performs and learn more about the business.

Yext (YEXT): Although it’s a new position, Yext has been on my radar for a few years now. I used to work with some people who now work at Yext, so I was familiar with the company even before they went public. Some investors that I really respect are pretty bullish on Yext, and that has played a big role in why I have opened a small position.

Additions to already existing positions: Sea Limited (SE), NovoCure (NVCR), Abiomed (ABMD), Guardant Health (GH), Baozun (BZUN), CRISPR Therapeutics (CRSP).

Watchlist

One thing I want to improve on in 2020 is being less impulsive in terms of starting new positions and selling current ones. One idea I have of enforcing that is to have a watchlist of stocks every quarter that I am considering buying or selling. Ideally I wouldn’t buy or sell any stock unless it was on my watchlist from the previous quarterly update. I don’t want to make it a hard and fast rule quite yet, but wanted to give it a try to see how it works. Here is my first watchlist:

Livongo Health (LVGO) – Interesting looking healthcare company which uses AI to provide “nudges” to people dealing with chronic diseases. Has a relatively unique subscription model as well.

MondoDB (MDB) – One of my lower conviction holdings (and I’m trying to concentrate my portfolio more). I’m still concerned by their ability to grow in a world with big players like AWS (Amazon Web Services). A contender for selling to deploy capital elsewhere.

Alibaba (BABA) – Another lower conviction holding. It’s already a big player in China. How much larger can they get? How do they perform with a possibly slowing Chinese economy?

Roku (ROKU) – I know I just started this position, but I hadn’t added it to the Freedom Portfolio until now because I had concerns about its ability to differentiate itself in the connected TV future. I’m not sure they have a defensible moat and am willing to sell if it looks like they’re losing ground to competitors or the landscape is changing.

Abiomed (ABMD) – Again, this was a position I just added to, but I think there are a lot of questions swirling around Abiomed that will get answered in the next quarter or two. Can they turn things around and get growth back on track? I think so, but if I end up being wrong then I want to be able to get out quickly.

The Freedom Portfolio – January 2020

So where does the Freedom Portfolio stand going into 2020? Well, thanks to the incredible performance of Shopify and Mercado Libre, it’s interestingly top-heavy with 3 Babylon 5 level positions yet no Enterprise level positions. I don’t expect this to last for too long, however, as Disney and Netflix are right on the cusp and both feel primed to have a strong 2020. Need a reminder of what these terms mean? Check out: Defining my Terms.

Thanks, as always, for reading, and here’s to a prosperous new decade for all investors.